Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMS 2022 | Recent updates from the PROMISE study

Annie Cowan • 26 Aug 2022
IMS 2022
Multiple Myeloma

Annie Cowan, BA, Dana-Farber Cancer Institute, Boston, MA, shares some updates from the PROMISE study (NCT03689595), which is screening high-risk individuals for precursor conditions including monoclonal gammopathy of undetermined significance (MGUS) and monoclonal gammopathy of indeterminate potential (MGIP). This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

More from Annie Cowan

Insights into the mechanisms leading to progression from MGUS and SMM to multiple myeloma 1:50
Insights into the mechanisms leading to progression from MGUS and SMM to multiple myeloma
Annie Cowan • 26 Aug 2022
An update on the PANGEA model 3:24
An update on the PANGEA model
Annie Cowan • 26 Aug 2022
An insight into MGIP and its role in the development of precursor conditions 1:35
An insight into MGIP and its role in the development of precursor conditions
Annie Cowan • 10 Apr 2022
The PANGEA model: improving risk stratification in multiple myeloma 5:04
The PANGEA model: improving risk stratification in multiple myeloma
Annie Cowan • 10 Apr 2022

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals